Showing results (1-10 of 56) with videos related to
Sort By:
Pageof 6
STAR Protocols|March 11, 2023
Longitudinal tracking of T cell lymphomas in mice using flow cytometryElizabeth A Kuczynski, Larissa Carnevalli, Charles SinclairBiorxiv : the Preprint Server for Biology|July 29, 2024
A linear ontogeny accounts for the development of naive, memory and tumour-infiltrating regulatory T cells in miceSanmoy Pathak, Thea Hogan, Sanket Rane, et al.Science Immunology|June 20, 2025
A linear ontogeny accounts for the development of naive, memory, and tumor-infiltrating regulatory T cells in miceSanmoy Pathak, Thea Hogan, Sanket Rane, et al.Angiogenesis|December 23, 2019
Vessel co-option and resistance to anti-angiogenic therapyElizabeth A Kuczynski, Andrew R ReynoldsChinese Journal of Cancer|November 27, 2016
Implications of vessel co-option in sorafenib-resistant hepatocellular carcinomaElizabeth A Kuczynski, Robert S KerbelOncoimmunology|September 18, 2018
Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunitySophie Langdon, Adina Hughes, Molly A Taylor, et al.Oncology|October 12, 2011
VEGFR2 expression and TGF-β signaling in initial and recurrent high-grade human gliomaElizabeth A Kuczynski, Steven G Patten, Brenda L CoomberCancer|June 22, 2011
Colorectal carcinoma cell production of transforming growth factor beta decreases expression of endothelial cell vascular endothelial growth factor receptor 2Elizabeth A Kuczynski, Alicia M Viloria-Petit, Brenda L CoomberEMBO Molecular Medicine|May 5, 2022
A preclinical model of peripheral T-cell lymphoma GATA3 reveals DNA damage response pathway vulnerabilityElizabeth A Kuczynski, Giulia Morlino, Alison Peter, et al.Nature Reviews. Clinical Oncology|September 4, 2013
Drug rechallenge and treatment beyond progression--implications for drug resistanceElizabeth A Kuczynski, Daniel J Sargent, Axel Grothey, et al.Pageof 6